PMID- 30075583
OWN - NLM
STAT- MEDLINE
DCOM- 20180827
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 31
DP  - 2018 Aug
TI  - Efficacy and safety of apatinib in advance osteosarcoma with pulmonary 
      metastases: A single-center observational study.
PG  - e11734
LID - 10.1097/MD.0000000000011734 [doi]
LID - e11734
AB  - This study was designed to evaluate the efficacy and safety of apatinib in 
      patients with advanced osteosarcoma and pulmonary metastases following failed 
      first-line chemotherapy.There were 10 patients with osteosarcoma pulmonary 
      metastases, whose first-line chemotherapy had failed, had received apatinib 
      treatment as a single agent. All patients had at least 1 measurable lung tumor. 
      Progression free survival (PFS), overall survival (OS), objective response rate 
      (ORR), disease control rate (DCR), and treatment-related adverse effects (AEs) 
      were reviewed and evaluated. Tumor response was assessed by response evaluation 
      criteria in solid tumor criteria (RECIST). The 10 patients in this study received 
      apatinib treatment for 2 to 16 months with a median of 7.5 months. The median PFS 
      was 7.5 months. The 6-month, 8-month, and 10-month PFS rates were 60%, 40% and 
      26.6%, respectively. The median OS was 14 months. After 6-month apatinib 
      treatment, 2 patients achieved partial response and 5 patients achieved stable 
      disease, while 3 patients were evaluated as progression of the disease. At the 
      6-month follow-up, the ORR was 20.0% and the DCR was 70.0%. Hand-foot syndrome 
      with grade 1/2 was the most common treatment-related AE. No drug-related severe 
      AEs occurred.After failed first-line chemotherapy, apatinib as a single agent 
      exhibited efficacy and acceptable safety in patients with advanced osteosarcoma 
      and pulmonary metastases.
FAU - Zheng, Kai
AU  - Zheng K
AD  - Orthopedic Department, The General Hospital of Jinan Military Commanding Region, 
      Jinan, China.
FAU - Xu, Ming
AU  - Xu M
FAU - Wang, Lei
AU  - Wang L
FAU - Yu, Xiuchun
AU  - Yu X
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Pyridines)
RN  - 5S371K6132 (apatinib)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antineoplastic Agents/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Bone Neoplasms/*drug therapy/mortality/*pathology
MH  - Child
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*secondary
MH  - Male
MH  - Osteosarcoma/*drug therapy/mortality/*pathology
MH  - Pyridines/administration & dosage/adverse effects/*therapeutic use
MH  - Survival Analysis
MH  - Young Adult
PMC - PMC6081168
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2018/08/05 06:00
MHDA- 2018/08/28 06:00
PMCR- 2018/08/03
CRDT- 2018/08/05 06:00
PHST- 2018/08/05 06:00 [entrez]
PHST- 2018/08/05 06:00 [pubmed]
PHST- 2018/08/28 06:00 [medline]
PHST- 2018/08/03 00:00 [pmc-release]
AID - 00005792-201808030-00093 [pii]
AID - MD-D-18-01967 [pii]
AID - 10.1097/MD.0000000000011734 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Aug;97(31):e11734. doi: 10.1097/MD.0000000000011734.